The subgroup analyses of intracranial progression-free survival (iPFS) depend on EGFR mutation subtype (A), patients age (B) and BM-related (symptomatic vs. asymptomatic) (C); HR, hazard ratio; BM, brain metastases; RT, radiotherapy; TKIs, tyrosine kinase inhibitors; EGFR, epidermal growth factor receptor.